Akèy › Maladi selil fòs › Illinois › Chicago
Etid klinik pou Maladi selil fòs nan Chicago, IL
18 etid pou Maladi selil fòs ap chèche patisipan nan sit nan ak bò kote Chicago (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease
Ap rekriteFaz 1
- University of Illinois at Chicago College of Medicine, Chicago
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Ap rekriteFaz 3
- Uni of Illinois Hospital and HSC, Chicago
A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
Ap rekriteFaz 1
- University of Illinois Hospital and Health Sciences System, Chicago
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
Ap rekriteFaz 3
- Univer Of Illinois at Chicago, Chicago
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Ap rekriteFaz 3
- Childrens Hospital of Chicago, Chicago
- Univer Of Illinois at Chicago, Chicago
Tocilizumab for Acute Chest Syndrome
Ap rekriteFaz 2
- University of Chicago, Chicago
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
Ap rekriteFaz 1/2Volontè an sante akeyi
- Local Institution - 0034, Chicago
A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
Ap rekriteFaz 2/3
- University of Illinois at Chicago Clinical Research Center, Chicago
- University of Illinois Hospital and Health Sciences System - Investigational Drug Services (IDS), Chicago
- University of Illinois Hospital and Health Sciences System, Chicago
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Ap rekriteEtid obsèvasyon
- Rush University Medical Center, Chicago
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
Ap rekriteFaz 2
- University of Illinois at Chicago, Chicago
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
Ap rekriteFaz 3
- University of Illinois-Chicago - College of Medicine- Site Number : 8400054, Chicago
Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease
Ap rekriteFaz 2
- University of Illinois at Chicago, Chicago
Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
Ap rekriteEtid obsèvasyon
- Comer Children's Hospital (MRD-HCT), Chicago
Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin
Ap rekriteFaz 2
- University of Illinois Chicago, Sickle Cell Center, Chicago
Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease
Ap rekrite
- University of Illinois at Chicago, Chicago
Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
Ap rekriteFaz 2
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
Ap rekrite
- Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago
Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease
Ap rekriteEtid obsèvasyon
- University of Illinois, Chicago
Etid Maladi selil fòs nan lòt vil
- Atlanta, GA22 etid
- Washington, DC20 etid
- Memphis, TN18 etid
- Philadelphia, PA15 etid
- Birmingham, AL14 etid
- New York City, NY13 etid
- St. Louis, MO12 etid
- Durham, NC10 etid
- Cincinnati, OH10 etid
- Houston, TX10 etid
- Boston, MA10 etid
- Pittsburgh, PA9 etid
Lòt etid nan Chicago
- Kansè Poumon ki pa ti selil61 etid
- Kansè nan tete58 etid
- Kansè (tout kalite)51 etid
- Kansè Metastatik45 etid
- Kansè pwostat45 etid
- Obèsite41 etid
- Kansè poumon41 etid
- Kansè ovè36 etid
- Akidan serebavaskilè34 etid
- Kansè kolorektal33 etid
- Ensifizyans kadyak31 etid
- Sipwa28 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.